We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

46 hedge funds and large institutions have $22.4M invested in Regulus Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 0.32% → 0.36% (+0.04%)

21% less funds holding

Funds holding: 58 → 46 (-12)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

32% less capital invested

Capital invested by funds: $33.1M → $22.4M (-$10.7M)

52% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 21

53% less call options, than puts

Call options by funds: $19K | Put options by funds: $40K

Holders
46
Holders Change
-12
Holders Change %
-20.69%
% of All Funds
1.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
14
Closed
21
Calls
$19K
Puts
$40K
Net Calls
-$21K
Net Calls Change
+$72K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$3.69M
2
EC
EcoR1 Capital
California
+$3.06M
3
Millennium Management
Millennium Management
New York
+$654K
4
Goldman Sachs
Goldman Sachs
New York
+$335K
5
LP
LMR Partners
United Kingdom
+$231K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.22M
2
State Street
State Street
Massachusetts
-$762K
3
Northern Trust
Northern Trust
Illinois
-$473K
4
TCIM
TIAA CREF Investment Management
New York
-$203K
5
Renaissance Technologies
Renaissance Technologies
New York
-$195K
Name Holding Trade Value Shares
Change 		Change in
Stake
Mariner
26
Mariner
Kansas
$37K – – –
State Street
27
State Street
Massachusetts
$32K -$762K -4,567 -94%
UBS Group
28
UBS Group
Switzerland
$31K -$8.18K -49 -16%
VKH
29
Virtu KCG Holdings
New York
$26K +$37.1K +222 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$24K -$128K -766 -79%
Macquarie Group
31
Macquarie Group
Australia
$20K – – –
JP Morgan Chase
32
JP Morgan Chase
New York
$17K +$23.4K +140 New
IA
33
IFP Advisors
Florida
$15K +$7.01K +42 +51%
Citadel Advisors
34
Citadel Advisors
Florida
$11K -$27.9K -167 -64%
DY
35
Dowling & Yahnke
California
$11K – – –
HighTower Advisors
36
HighTower Advisors
Illinois
$10K – – –
LTFS
37
Ladenburg Thalmann Financial Services
Florida
$9K – – –
Group One Trading
38
Group One Trading
Illinois
$9K +$3.34K +20 +34%
PAM
39
Panagora Asset Management
Massachusetts
$2K – – –
Creative Planning
40
Creative Planning
Kansas
$1K -$20.9K -125 -94%
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K -$167 -1 -8%
MAM
42
Meeder Asset Management
Ohio
$1K – – –
SIM
43
Sonora Investment Management
Arizona
$197 – – –
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$4 -$501 -3 Closed
TCIM
45
TIAA CREF Investment Management
New York
– -$203K -1,027 Closed
Renaissance Technologies
46
Renaissance Technologies
New York
– -$195K -986 Closed
Tudor Investment Corp
47
Tudor Investment Corp
Connecticut
– -$178K -901 Closed
TA
48
Teachers Advisors
New York
– -$152K -769 Closed
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
– -$131K -664 Closed
Charles Schwab
50
Charles Schwab
California
– -$102K -515 Closed
1
2
3

RGLS Hedge Fund Activity: Q2 2017 in Review

46 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2017, worth a combined $22.4M — down 32% from $33.1M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of RGLS and 10 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was BVF Inc, adding an estimated $3.69M. The largest seller was BlackRock, cutting an estimated $2.22M.

  • 46 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2017, down from 58 in Q1 2017.
  • Funds reported $22.4M of Regulus Therapeutics stock for Q2 2017, down 32% quarter-over-quarter.
  • 10 funds opened new Regulus Therapeutics positions in Q2 2017 and 21 closed out, a net change of -11 holders.
  • The largest Regulus Therapeutics buyer in Q2 2017 was BVF Inc, an estimated $3.69M added.
  • The largest Regulus Therapeutics seller in Q2 2017 was BlackRock, an estimated $2.22M sold.

Based on aggregated 13F filings for Q2 2017.